Skip to main content
Fig. 4 | Antimicrobial Resistance & Infection Control

Fig. 4

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Fig. 4

Results from probabilistic sensitivity analysis for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence, on cost-effectiveness plane. Abbreviations: CAZ-AVI, ceftazidime-avibactam; QALY, quality-adjusted life year; WTP, willingness-to-pay

. CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Ceftolozane/tazobactam sequence: Ceftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Notes: Each dot represents the cost-effectiveness outcome from each iteration. The threshold lines represent cost-effectiveness thresholds of € 30,000 or € 40,000 per QALY (i.e., the maximum amount society is willing to pay for a QALY gained). In cases that fall to the right and below this line, the CAZ-AVI sequence is cost effective compared to the ceftolozane/tazobactam sequence. In cases that fall to left and above this line, the CAZ-AVI sequence is not cost effective compared to the ceftolozane/tazobactam sequence

Back to article page